Secretin vs Efinopegdutide
Head-to-head comparison of Secretin (Human Secretin) and Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Secretin | Efinopegdutide |
|---|---|---|
| Category | Gastrointestinal | Weight Management |
| Full Name | Human Secretin | Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 3055.4 Da | N/A |
| Half-Life | 5-7 minutes | Approximately 1 week |
| Amino Acids | 27 | N/A |
| Typical Dose | 0.2 mcg/kg IV | Trial-dependent; weekly SC dosing |
| Route | Intravenous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 800 | 14 |
| Research Status | Clinical | Clinical |
Secretin Benefits
- ✓stimulates-pancreatic-secretion
- ✓supports-bicarbonate-release
- ✓aids-duodenal-pH-control
- ✓helps-digestive-coordination
Efinopegdutide Benefits
- ✓reduced body weight
- ✓improved insulin sensitivity
- ✓reduced liver fat
- ✓greater satiety
Secretin Dosing
0.2 mcg/kg IV diagnostic dose|research infusion protocols|short bolus administration
Efinopegdutide Dosing
once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials
Secretin Side Effects
- ⚠flushing
- ⚠nausea
- ⚠abdominal-cramping
Efinopegdutide Side Effects
- ⚠nausea
- ⚠decreased appetite
- ⚠fatigue
Research Overview
Secretin
Secretin is a classic GI hormone with extensive physiology literature and established diagnostic use. It remains important for studying pancreatic secretory function, biliary responses, and duodenal feedback.
Efinopegdutide
Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.